

# Influenza Therapeutic Landscape

Phase 1

Phase 2

Phase 3

Market

Viral Targets

Host Targets

**Atriva**  
ATR-002  
MEK inhibitor

**Fab'entech**  
Equine  
Polyclonal H5

**SAREPTA**  
Radavirsen  
Antisense RNA

**VIR**  
VIR-2482  
Prophylactic mAb

**FEBICO**  
Far East Bio Tec. Co., Ltd  
遠東生技  
Apomivir  
Spirulina extract

**CELLTRION**  
CT-P27  
2 HA Anti-stem  
mAbs

**The University of Hong Kong**  
Flufenamic  
acid (FFA)  
NSAID

**phs Pharmstandard**  
Arbidol  
Umifenovir  
fusion inhibitor

**M2 Inhibitors**  
**Forest Pharmaceuticals, Inc.**  
Flumadine  
(Rimantadine)

**DAIICHI-SANKYO**  
Inavir  
(Laninamivir)  
(Japan only)

**Autoimmune Technologies**  
Flufirvitide-3  
HA inhibitor

**以岭药业**  
YILING PHARMACEUTICAL  
KT07  
herb mix

**MedImmune**  
MEDI8852  
HA Anti-stem  
mAb

**FUJIFILM**  
Favipiravir  
Polymerase  
inhibitor

**ENDO PHARMACEUTICALS**  
Symmetrel  
(Amantadine)

**BioCRYST**  
Rapivab  
(Peramivir)

**Visterra**  
VIS-410  
HA Anti-stem  
mAb

**ZSP1273**  
Polymerase  
inhibitor

**Janssen**  
Pimodivir  
PB2 inhibitor

**PA Inhibitor**  
**Roche** **SHIONOGI**  
Xofluza  
(Baloxavir)

**gsk** GlaxoSmithKline  
Relenza  
(Zanamivir)

**Roche**  
Tamiflu  
(Oseltamivir)

**Gemmus PHARMA**  
GP1001  
Anti-inflammatory  
agent

**pulmatrix**  
PUR003  
cationic airway  
lining  
modulator

**Karyopharm**  
Verdinexor  
Nuclear export  
inhibitor

**HEMISPHERE**  
BIOPHARMA, INC.  
Alferon LDO  
INF- $\alpha$ 3

**Beth Israel Deaconess Medical Center**  
Atorvastatin

**CSPC**  
Baicalein  
Anti-inflammatory

**The University of Hong Kong**  
Celecoxib

**Centre Hospitalier Régional**  
Diltiazem

**ANSUN**  
FLUDASE  
Sialidase

**VENTALEON**  
LASAG  
acetylsalicylic  
acid

**Romark Laboratories, L.C.**  
Nitazoxanide

**emergo therapeutics**  
Norketotifen  
Anti-histamine

**Other**  
**Inhaled**  
**IV**  
**Oral**

Updated Jan 2020